What Therapies Target Cell-Cell Interactions in Cancer?
Several therapies aim to disrupt harmful cell-cell interactions in cancer. For instance, immune checkpoint inhibitors like pembrolizumab block the interaction between PD-1 and PD-L1, enhancing the immune system's ability to target cancer cells. Anti-angiogenic therapies, such as bevacizumab, inhibit the formation of new blood vessels that supply the tumor. Additionally, therapies targeting cancer-associated fibroblasts and other components of the TME are under investigation.
